Pharma in Focus
Email Address Sign-Up

Australia's most trusted source of pharma news


Gilead's $29bn buy arrives

Posted 23 December 2020 AM

A first-in-class breast cancer immunotherapy recently acquired by Gilead has made its first appearance in Australia with the TGA granting the drug a priority review determination.

Trodelvy is a Trop-2 directed antibody-drug conjugate which the company added to its oncology pipeline when it bought Immunomedics in October for approximately US$21 billion (AU$29 billion).

Looks like you've lost your access to Pharma in Focus. To restore access or update your subscription, click here

Top of the Hill
Biden and the MA agreement
'Global decisions' will influence ongoing negotiations
Special Report
PBAC March agenda
Every major and minor sub sorted by indication
Special Report
Aust Covid Vaccine Tracker
UPDATE: Distribution of two mRNA vaccines overseas